ENTITY
Junshi Biosciences

Junshi Biosciences (1877 HK)

309
Analysis
Health Care • China
Junshi Biosciences is an innovation-driven biopharmaceutical company focused on the discovery, development, clinical research, and commercialization of innovative therapeutics. Its key products, including toripalimab injection, Etesevimab, and adalimumab injection, are used to treat malignant tumors, autoimmune diseases, chronic metabolic diseases, nervous system diseases, and infectious diseases. The company was founded in December 2012 and is headquartered in Shanghai, China.
more
Exchange Announcement • 24 Sep 2026 16:30

2026 Interim Report

Exchange Announcement • 23 Sep 2026 21:15

Reserved Grant Of A Share Options, Fulfilment Of The Exercise Conditions For The First Exercise Period And Cancellation Of Certain A Share Options Of The First Grant Of A Share Options Under The 2025 A Share Option Incentive Scheme

Exchange Announcement • 23 Sep 2026 20:47

Overseas Regulatory Announcement - Shanghai Junshi Biosciences Co., Ltd.* Announcement On The Resolutions Of The Twenty-Third Meeting Of The Fourth Session Of The Board Of Directors

Exchange Announcement • 04 Sep 2026 20:53

Overseas Regulatory Announcement - Shanghai Junshi Biosciences Co., Ltd.* Announcement On The Convening Of The 2026 Interim Results Briefing

Exchange Announcement • 31 Aug 2026 07:57

Overseas Regulatory Announcement - Shanghai Junshi Biosciences Co., Ltd.* Announcement On The Plan For The Reduction In The Shareholding Of The Shareholder

x